Boston Scientific Corp
BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3053% below fair value
$43.64+0.61 (+1.42%)
Close on Nov 18, 2026Market cap $63.24BP/E 17.7Yield –
Boston Scientific GAAP EBITDA: $1,191M in Q3 2026, down 12.6% from a year earlier.
Latest, Q3 2026
1,191
Period ended Sep 30, 2026
Change on a year earlier
-12.6%
1,362 in Q3 2025
History
18 quarters
Since Q2 2022
Sources
15
Documents cited below
Where the Q3 2026 figure comes from
“EBITDA 1,141 1,588 1,500 1,191 $ 5,419”
Source: BSX FY2026Q3 Financial & Operational Highlights Presentation ↗
Reported in Quarterly FOH Appendix C.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Boston Scientific GAAP EBITDA ($M), quarterly Q2 2022–Q3 2026 [Data set]. Compiled from Boston Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/bsx/kpis/lev-gaap-ebitda
See every metric in the Boston Scientific KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?